These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 24524927)

  • 1. Is the breast cancer drug tamoxifen being sold as a bodybuilding dietary supplement?
    Evans-Brown M; Kimergård A; McVeigh J; Chandler M; Brandt SD
    BMJ; 2014 Feb; 348():g1476. PubMed ID: 24524927
    [No Abstract]   [Full Text] [Related]  

  • 2. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
    Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
    J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disclaimers in dietary supplement print advertising: the bodybuilding category as a model case for change.
    Soller RW; Rice LG; Ambrose PJ
    Food Drug Law J; 2007; 62(2):375-86. PubMed ID: 17632967
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
    Boccardo F; Rubagotti A; Battaglia M; Di Tonno P; Selvaggi FP; Conti G; Comeri G; Bertaccini A; Martorana G; Galassi P; Zattoni F; Macchiarella A; Siragusa A; Muscas G; Durand F; Potenzoni D; Manganelli A; Ferraris V; Montefiore F
    J Clin Oncol; 2005 Feb; 23(4):808-15. PubMed ID: 15681525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
    Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy?
    Viani GA; Bernardes da Silva LG; Stefano EJ
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e519-24. PubMed ID: 22704706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.
    Saltzstein D; Sieber P; Morris T; Gallo J
    Prostate Cancer Prostatic Dis; 2005; 8(1):75-83. PubMed ID: 15685254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.
    Serretta V; Altieri V; Morgia G; Nicolosi F; De Grande G; Mazza R; Melloni D; Allegro R; Ferraù F; Gebbia V
    Clin Genitourin Cancer; 2012 Sep; 10(3):174-9. PubMed ID: 22502790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy.
    Premkumar VG; Yuvaraj S; Shanthi P; Sachdanandam P
    Br J Nutr; 2008 Dec; 100(6):1179-82. PubMed ID: 18377693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
    Fradet Y; Egerdie B; Andersen M; Tammela TL; Nachabe M; Armstrong J; Morris T; Navani S
    Eur Urol; 2007 Jul; 52(1):106-14. PubMed ID: 17270340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen for flutamide/finasteride-induced gynecomastia.
    Staiman VR; Lowe FC
    Urology; 1997 Dec; 50(6):929-33. PubMed ID: 9426725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bodybuilding, energy, and weight-loss supplements are associated with deployment and physical activity in U.S. military personnel.
    Jacobson IG; Horton JL; Smith B; Wells TS; Boyko EJ; Lieberman HR; Ryan MA; Smith TC;
    Ann Epidemiol; 2012 May; 22(5):318-30. PubMed ID: 22445519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of marked gynecomastia in puberty with tamoxifen].
    König R; Schönberger W; Neumann P; Benes P; Grimm W
    Klin Padiatr; 1987; 199(6):389-91. PubMed ID: 3123765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histopathological effects of tamoxifen in the treatment of pubertal gynecomastia.
    Akgül S; Kanbur N; Güçer S; Safak T; Derman O
    J Pediatr Endocrinol Metab; 2012; 25(7-8):753-5. PubMed ID: 23155705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.
    Lawrence SE; Faught KA; Vethamuthu J; Lawson ML
    J Pediatr; 2004 Jul; 145(1):71-6. PubMed ID: 15238910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
    Van Poppel H
    Eur Urol; 2007 Jul; 52(1):115. PubMed ID: 17270341
    [No Abstract]   [Full Text] [Related]  

  • 17. Idiopathic gynecomastia treated with tamoxifen: a preliminary report.
    Alagaratnam TT
    Clin Ther; 1987; 9(5):483-7. PubMed ID: 3664552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia.
    Ting AC; Chow LW; Leung YF
    Am Surg; 2000 Jan; 66(1):38-40. PubMed ID: 10651345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients.
    Bedognetti D; Rubagotti A; Conti G; Francesca F; De Cobelli O; Canclini L; Gallucci M; Aragona F; Di Tonno P; Cortellini P; Martorana G; Lapini A; Boccardo F
    Eur Urol; 2010 Feb; 57(2):238-45. PubMed ID: 19481335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of size and duration of gynecomastia on its response to treatment with tamoxifen].
    Devoto C E; Madariaga A M; Lioi C X; Mardones N
    Rev Med Chil; 2007 Dec; 135(12):1558-65. PubMed ID: 18357357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.